Associations of semaglutide with first-time diagnosis of Alzheimer's disease in patients with type 2 diabetes: Target trial emulation using nationwide real-world data in the US
- Design
- Retrospective cohort · 1094761 participants · Hard outcome
- Match to healthy normal-weight adults aged 55–75
- Different populationType 2 diabetes; EHR diagnoses; 3-year window is short for AD onset, suggesting detection or reverse-causation effects.
- Could weight loss explain it?
- Possibly[Auto] Participants had obesity and/or type 2 diabetes and the abstract does not separate direct drug effects from weight loss or glycaemic improvement.
- Study tier
- Study tier 4Hypothesis-generating EHR emulation; effect sizes implausibly large for a 3-year window; contradicted by evoke RCTs in established AD.
- Assessment
- Version 2 · curated · Sep 13, 2026
Study facts come from the paper. Population match, weight-loss explanation and study tier are our judgments, made against the reference group of healthy normal-weight adults aged 55–75.
In US electronic records of people with type 2 diabetes, semaglutide users were 40-70% less likely to receive a first Alzheimer's diagnosis within 3 years than users of other diabetes drugs. The size and speed of the effect suggest bias (people with early cognitive decline may not be prescribed new injectables); the evoke trials found no effect on AD progression.
01Findings
What the study reported
- Drugs
- Semaglutide
- Comparator
- seven other antidiabetic drug classes
- Primary outcome
- First-time Alzheimer's disease diagnosis within 3 years
- Effect
- HR 0.33 vs insulin; HR 0.59 vs other GLP-1RAs
- 95% confidence interval
- 0.21 to 0.51; 0.37 to 0.95
- Follow-up
- 3 years
- Adverse events
- Not extracted
- Limitations
- Auto-classified from abstract only; effect estimates, adverse events and limitations not extracted. Requires manual review.
Who was studied
- Obesity status
- obesity/overweight present (all or most)
- Diabetes status
- type 2 diabetes required
- Baseline condition
- Alzheimer's disease / MCI
Study quality details
- Study design
- Retrospective cohort
- Sample size
- not extracted
- Randomization
- no
- Blinding
- not stated
- Comparator
- not stated
- Follow up duration
- not stated
- Outcome type
- unknown
- Replication
- not assessed (auto)
- Consistency with other evidence
- not assessed (auto)
- Population applicability
- INDIRECT
- Statistical precision
- large
- Risk of bias
- reverse causation (prodromal AD reduces prescribing), coded outcomes, short window
- Funding conflicts
- no
- Peer review status
- yes
02Funding
Funding and conflicts
- Funding
- NIH (NIA)
- Industry funded
- No
- Manufacturer
- None identified
- Sponsor role
- no manufacturer funding identified
- Author conflicts
- Authors declare no competing interests.
- Independent replication
- consistent with other EHR cohorts; not with RCTs
Funding is shown on every study and never used to score it.
03Claims
Claims this study bears on
- GLP-1 receptor agonist treatment reduces the risk of developing dementia.Supports
EHR emulation in T2D: semaglutide associated with 40-70% lower first AD diagnosis; short 3-year window; diagnosis-code outcome.
04Source
The source, as retrieved
Abstract
[INTRODUCTION] Emerging preclinical evidence suggests that semaglutide, a glucagon-like peptide receptor agonist (GLP-1RA) for type 2 diabetes mellitus (T2DM) and obesity, protects against neurodegeneration and neuroinflammation. However, real-world evidence for its ability to protect against Alzheimer's disease (AD) is lacking. [METHODS] We conducted emulation target trials based on a nationwide database of electronic health records (EHRs) of 116 million US patients. Seven target trials were emulated among 1,094,761 eligible patients with T2DM who had no prior AD diagnosis by comparing semaglutide with seven other antidiabetic medications. First-ever diagnosis of AD occurred within a 3-year follow-up period and was examined using Cox proportional hazards and Kaplan-Meier survival analyses. [RESULTS] Semaglutide was associated with significantly reduced risk for first-time AD diagnosis, most strongly compared with insulin (hazard ratio [HR], 0.33 [95% CI: 0.21 to 0.51]) and most weakly compared with other GLP-1RAs (HR, 0.59 [95% CI: 0.37 to 0.95]). Similar results were seen across obesity status, gender, and age groups. [DISCUSSION] These findings support further studies to assess semaglutide's potential in preventing AD. [HIGHLIGHTS] Semaglutide was associated with 40% to 70% reduced risks of first-time AD diagnosis in T2DM patients compared to other antidiabetic medications, including other GLP-1RAs. Semaglutide was associated with significantly lower AD-related medication prescriptions. Similar reductions were seen across obesity status, gender, and age groups. Our findings provide real-world evidence supporting the potential clinical benefits of semaglutide in mitigating AD initiation and development in patients with T2DM. These findings support further clinical trials to assess semaglutide's potential in delaying or preventing AD.
Where this record came from
| Source | Retrieved | Identifier |
|---|---|---|
| pubmed | Sep 13, 2026 | 39445596 first ingestion |